BridgeBio Pharma’s ML Bio Solutions Announces Dosing of First Subject in Phase 1 Clinical Trial of BBP-418 For Limb Girdle Muscular Dystrophy Type 2i (LGMD2i)

06.11.2020

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

06.05.2020

BridgeBio Pharma’s QED Therapeutics Presents Data on Infigratinib in Cholangiocarcinoma and Urothelial Carcinoma at the American Society of Clinical Oncology 2020 Virtual Scientific Program

05.29.2020

BridgeBio Pharma’s Phoenix Tissue Repair Provides Updates to its Recessive Dystrophic Epidermolysis Bullosa (RDEB) Program and Announces New Leadership Appointments

05.13.2020

BridgeBio Pharma, Inc. Reports First Quarter 2020 Financial Results and Business Update

05.13.2020

BridgeBio Pharma’s QED Therapeutics Announces Preclinical Data Demonstrating Potential of Low-Dose Infigratinib in Achondroplasia

05.11.2020

BridgeBio Pharma, Inc. To Present At Upcoming Investor Conference

05.06.2020

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

05.05.2020

A Letter to Our Shareholders from CEO Neil Kumar

04.23.2020

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

04.03.2020

An Open Letter to Patients and Their Families from BridgeBio Pharma CEO Neil Kumar

03.19.2020

BridgeBio Pharma’s QED Therapeutics Announces Dosing of First Patients in Phase 3 and Phase 2 Clinical Trials of Infigratinib in Tumors with FGFR Genetic Alterations

03.12.2020

BridgeBio Pharma, Inc. Prices Upsized Offering of $475 Million Convertible Senior Notes

03.04.2020

BridgeBio Pharma, Inc. Announces Proposed Offering of $350 Million Convertible Senior Notes

03.04.2020

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

03.03.2020

BridgeBio Pharma Reports Fourth Quarter and Full Year 2019 Financial Results and Highlights Portfolio Progress

03.02.2020

BridgeBio Pharma, Inc. Appoints Ronald J. Daniels To Its Board Of Directors

02.24.2020

BridgeBio Pharma And Eidos Therapeutics To Present At Upcoming Investor Conferences

02.21.2020

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

02.05.2020

BridgeBio Pharma Grows Pipeline to 20+ Genetic Medicines with Four Assets Focused on Treating Genetically Driven Diseases at Their Source

01.13.2020

news

Catch up on news from BridgeBio and its companies and follow developments about the promising treatments in our pipeline. Follow us on LinkedIn and Twitter to keep up with all the latest news.

Links to an external site